Maxim Upgrades Gilead Sciences (GILD) to 'Buy'
On May 20, Maxim analyst Michael Okunewitch upgraded Gilead Sciences from 'Hold' to 'Buy', citing strong growth potential in its key products and core business. The firm set a price target of $165 for the stock, implying over 25% upside.
Tickers: $GILD
Topics: Biopharmaceuticals Dividend Stocks Earnings Guidance